breast cancer survivors
Breast Cancer Survivors
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Nature. Vol. 434, p. 917-921, April 2005.
The
risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
Kelly Metcalfe, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner
E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, Narod SA.
Gynecologic Oncology. Volume 96,
Issue 1: p. 222-226,
January 2005.
A
combined analysis of outcome following breast cancer: differences in survival
based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Mark E. Robson, Pierre O. Chappuis, Jaya Satagopan, Nora Wong, Jeff
Boyd, John R. Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R.
Bégin,
Kenneth Offit, and William D. Foulkes. Breast Cancer Research. Volume 6, Number 1: R8-R17, October 2003.
BRCA1
functions as a differential modulator of chemotherapy-induced apoptosis
Jennifer E. Quinn, Richard D. Kennedy, Paul B. Mullan, Paula M. Gilmore, Michael
Carty, Patrick G. Johnston and D. Paul Harkin.
Cancer Research. Volume 63: p. 6221-6228, October 2003.
Impact
of germline BRCA 1 mutations and overexpression of P53 on prognosis and response
to treatment following breast carcinoma: 10-year follow-up data
John R. Goffin, M.D., Pierre O. Chappuis, M.D., Louis R. Bégin, M.D.,
Nora Wong, M.Sc., Jean-Sébastien Brunet, M.Sc., Nancy Hamel, M.Sc.,
Ann-Josée Paradis, B.Sc., Jeff Boyd, Ph.D., William D. Foulkes, M.B.,
Ph.D..
Cancer. Volume 97, Issue 3: p. 527-536, January 2003.
Survival
in prospectively ascertained familial breast cancer: Analysis of a series
stratified by tumour characteristics, BRCA mutations and oophorectomy
Pål Møller, Åke Borg, D. Gareth Evans, Neva Haites, Marta
M. Reis, Hans Vasen, Elaine Anderson, C. Michael Steel, Jaran Apold, David
Goudie, Anthony Howell, Fiona Lalloo, Lovise Mæhle, Helen Gregory, Ketil
Heimdal.
International Journal of Cancer. Volume 101, Issue 6: p. 555-559,
August 2002.
Outcome of conservatively
managed early-onset breast cancer by Brca1/2 status
Bruce Haffty, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward
B, Carter D, Matloff E, Bale AE, Alvarez-Franco M.
Lancet. Volume 359, issue9316: p. 1471-7, April 2002.
Effect of BRCA
mutations on the length of survival in epithelial ovarian tumors
Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller,
G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, J. Menczer, B. Piura, J.P.
Struewing, B. Modan.
Journal of Clinical Oncology. Volume 20, Issue 2: p. 463-466, January
2002.
Effect of radiotherapy
after breast-conserving treatment in women with breast cancer and germline
BRCA1/2 mutations
Lori J. Pierce, Myla Strawderman, Steven A. Narod, Ivo Oliviotto, Andrea Eisen,
Laura Dawson, David Gaffney, Lawrence J. Solin, Asa Nixon, Judy Garber, Christine
Berg, Claudine Isaacs, Ruth Heimann, Olufunmilayo I. Olopade, Bruce Haffty,
Barbara L. Weber.
Journal of Clinical Oncology. Volume 18, Issue 19: p. 3360-3369,
October 2000.